[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus-in-remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus-in-remission":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100485179","prevalence-of-mafld-in-patients-with-type-2-diabetes-in-jiangsu-province-of-china-100485179",false,"NCT05597709","Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes\n* UAP were measured based on iLivTouch\n* Willing to attend this study and able to provide the written informed consent.\n\nExclusion Criteria:\n\n* Other types of diabetes\n* Patients unable to receive regular follow-up","ALL","18 Years",{"count":19,"type":20},2900,"ESTIMATED","OBSERVATIONAL","In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.",[24,25],"Type 2 Diabetes Mellitus in Remission","Metabolic Associated Fatty Liver Disease",[27,28,29],"Type 2 diabetes mellitus","Metabolic associated fatty liver disease","ultrasound attenuation parameter","RECRUITING","2022-10-24",{"date":33,"type":34},"2022-10-28","ACTUAL",{"date":36,"type":34},"2022-07-01",{"date":38,"type":20},"2027-06-01",{"name":40,"class":41},"Wuxi Hisky Medical Technology Co Ltd","INDUSTRY"]